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Abstract
Background: Transcranial direct current stimulation was suggested to provide beneficial effects in chronic migraine, a
condition often associated with medication overuse for which no long-term therapy is available.
Methods: We conducted a randomised controlled trial to assess long-term efficacy of transcranial direct current
stimulation. Adults diagnosed with chronic migraine and medication overuse were assigned to receive in a 1:1:1
ratio anodal, cathodal, or sham transcranial direct current stimulation daily for five consecutive days, along with stand-
ardised drug withdrawal protocol. Primary outcome was 50% reduction of days of headache per month at 12 months.
Co-secondary outcomes were 50% reduction of days of headache per month at 6 months, reduction of analgesic intake
per month, and change in disability and quality of life, catastrophising, depression, state and trait anxiety, dependence
attitude and allodynia intensity. Patients were not allowed to take any migraine prophylaxis drug for the entire study
period.
Results: We randomly allocated 135 patients to anodal (44), cathodal (45), and sham (46) transcranial direct current
stimulation. At 6 and 12 months, the percentage of reduction of days of headache and number of analgesics per
month ranged between 48.5% and 64.7%, without differences between transcranial direct current stimulation (cathodal,
anodal, or the results obtained from the two arms of treatment, anodal plus cathodal) and sham. Catastrophising
attitude significantly reduced at 12 months in all groups. There was no difference for the other secondary outcomes.
Conclusions: Transcranial direct current stimulation did not influence the short and long-term course of chronic
migraine with medication overuse after acute drug withdrawal. Behavioral and educational measures and support for
patients’ pain management could provide long-term improvement and low relapse rate.
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Introduction
Migraine is a complex clinical syndrome encompassing
a variety of somatic and autonomic symptoms, among
which pain is the most relevant and drives diagnosis
and treatments. Chronic migraine (CM) is a subtype
that the International Headache Society (IHS) classi-
fied as headache with a frequency at least for 15 days
per month with eight migraine days per month (1). It
affects about 2% of the migraine population and is a
particularly disabling condition with huge physical and
emotional burden and high direct and indirect costs (2).
CM patients are difficult to treat also because of the
high frequency of psychiatric comorbidities, like anxi-
ety and depression, and available pharmacological
therapies often cannot provide satisfactory pain relief.
The regular use of medications for the treatment of
primary migraine episodes can lead to an increased fre-
quency and intensity of migraine attacks (2). Such asso-
ciation with medication overuse (MO) makes the
overall treatment even more challenging. Drug with-
drawal is considered the first step for adequately man-
aging MO patients (2). However, only a few studies
reported findings at 12 months and none in the absence
of pharmacological prophylaxis (3,4).
In recent years, the efficacy of neurostimulation
techniques to treat migraine has been tested using dif-
ferent approaches in several clinical studies, with incon-
clusive results due to different reasons: No
standardised protocols of application, heterogeneous
groups of patients, short follow-up, poor criteria for
clinical efficacy measures (5,6). Transcranial direct cur-
rent stimulation (tDCS) is a technique of brain modu-
lation that in the last few years has been used in various
neurological and psychiatric disorders (7). It has the
advantage of allowing a reliable placebo condition to
test its efficacy in randomised trials (7), and it has been
proposed to provide beneficial effects in different types
of chronic pain (8–10). No conclusions could be drawn,
mainly because of the poor quality of most of the clin-
ical studies (11,12).
Transcranial direct current stimulation causes
polarity-dependent shifts of the resting membrane
potential and consequently could change neuronal
excitability at the site of stimulation and in the con-
nected areas. If the stimulation lasts long enough,
tDCS might induce neurophysiological and behaviou-
ral aftereffects, which are thought to depend on synap-
tic plasticity (7).
Given the results of previous studies suggesting that
a technique able to modulate pain-related neural net-
works, such as tDCS, could successfully treat CM
(5,6,13) and the emphasised need for confirmatory
trials with more robust methodology (14–17), we
designed a placebo-controlled, double-blind,
randomised clinical trial (RCT) combined with an
ensuing open-label study to assess, over 1-year
follow-up, the short-, mid- and long-term efficacy of
tDCS in patients diagnosed with CM and MO after
acute drug withdrawal and no migraine prophylaxis.
Methods
Trial protocol
This was a monocentre study carried out at the
Headache Centre of the IRCCS Foundation “Carlo
Besta” Neurological Institute of Milan, Italy in collab-
oration with the Department of Psychology of the
Milano Bicocca University, Milan, Italy. The trial
was performed in accordance with the declaration of
Helsinki and approved by the local Ethic Committee
on July 2015.
Participants were assessed for eligibility during a
screening visit in which inclusion and exclusion criteria
were applied (Figure 1). Upon inclusion, participants
were randomly assigned in 1:1:1 ratio to anodal tDCS,
cathodal tDCS, or sham stimulation, which started the
same day as the standardised acute drug withdrawal.
At the end of the recruitment for the RCT, we
started the open-label trial in which participants were
assigned to standardised acute drug withdrawal. This
arm was added to provide a pragmatic, non-parallel
comparison with acute drug withdrawal, which is con-
sidered the most effective treatment of CM with MO
(18). The reason why it was not added as one further
arm of the double-blind part of the study is because
results would have been biased by the lack of any active
or sham tDCS procedure, and therefore would have
not been comparable. Even though this approach had
the intrinsic limitation of a non-parallel analysis, we
thought it could have provided a clinically meaningful
comparison between the results from the RCT and the
current clinical practice, while ensuring the integrity of
the RCT.
Trial participants
Participants both in the RCT and the ensuing open
label study were adults diagnosed with CM and MO
according to the IHS criteria (1), who must have failed
at least two pharmacological prophylaxis therapies.
Diagnosis was confirmed on the basis of a daily head-
ache diary that all participants filled out in the last
month prior to the enrolment. All participants gave
written informed consent. Patients were not involved
in the design, conduct, reporting, or dissemination
plans for our research.
Exclusion criteria were a known diagnosis of major
depression or other major psychiatric disorders
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identified after psychiatric consultation, having a car-
diac pacemaker, clips for previous head surgery,
cochlear implant, a history of epilepsy, known idio-
pathic intracranial hypertension, harmful alcohol con-
sumption, and pregnancy.
Sample size calculation
Based on an expected effect of 50% in the sham group
at the 12-month visit (i.e. 50% of patients with a reduc-
tion of at least 50% of days of migraine/month) assum-
ing alpha¼ 0.1 and power¼ 80% to determine a
significant absolute difference of at least 30% (i.e. an
expected 80% of patients with a reduction of at least
50% of days of migraine/month) between any of the
groups (i.e. cathodic versus sham or anodic versus
sham), and assuming a loss to follow-up of 15%, we
estimated that 135 patients (45 per arm) should be
recruited and followed in the RCT for 12 months.
Randomisation and blindness
Participants in the RCT were assigned to the treatment
arms according to a centralised randomisation sched-
ule. The randomisation schedule was prepared in the
data management system by an independent trial stat-
istician. The two study neurologists (LG and SU), who
enrolled and followed the patients, were not involved in
the randomisation procedure and were blind to the
treatment condition. The two technicians (ES and
EG), who performed the tDCS procedures, were
aware of the treatment conditions but were not
involved in any of the clinical assessments.
Treatments
The day of randomisation, participants started a stand-
ardised acute drug withdrawal protocol (4) with intra-
venous administration of dexamethasone 4 mg and
ademetionine 200 mg in saline solution, and oral bro-
mazepam 1.5 mg three times daily, for five consecutive
days. The same day, they started the tDCS procedure
based on allocation (anodal, cathodal, or sham). Both
acute drug withdrawal and tDCS were performed daily
for five consecutive days.
The tDCS was delivered with a battery-driven con-
stant current stimulator (BrainStim, EMS srl, Bologna,
Italy; http://brainstim.it) through a pair of surface
saline-soaked sponge electrodes (35 cm, 7 5 cm)
placed on the patient’s scalp. The stimulation was
applied daily, for a duration of 20 minutes, current
intensity of 2mA, fade in/fade out phases¼ 10 sec, for
five consecutive days during the withdrawal program.
Patients were randomised to receive anodal, cathodal
or sham tDCS; in every case, the active electrode was
placed over the primary motor cortex of the right
No. 237 assessed for eligibility
No. 135
randomized
No. 44 received anodal tDCS as
assigned
No. 45 received cathodal tDCS
as assigned
No. 46 received sham tDCS as
assigned
No. 102 excluded
- No. 31 refused consent
- No. 25 psychiatric comorbidities
- No. 42 idiopathic intracranial
  hypertension
Inclusion criteria
    - Age 18–65 yrs
    - Diagnosis of CM-MO
    - No withdrawal intervention during
       the 6 months prior the study
No. 44 included in analysis No. 45 included in analysis No. 46 included in analysis
Figure 1. Trial profile.
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hemisphere (site C4 of the 10/20 EEG system) with the
reference electrode placed over the contralateral supra-
orbital area.
Motor cortex stimulation is thought to exert analge-
sic effects by activating descending pathways, hence
restoring inhibitory control of nociceptive transmis-
sion. The analgesic effects of tDCS occur through var-
ious neural circuits involved in sensori-discriminative,
cognitive, and emotional aspect of chronic pain (19).
Although theoretically having opposite effects on cor-
tical excitability, with anodal tDCS increasing cortical
excitability and cathodal tDCS decreasing it, both
polarities were found to be effective on pain (7). With
regard to chronic pain syndromes, also including
migraine, sham-controlled studies showed some posi-
tive results for both anodal and cathodal tDCS
(5,17,20). Hence, here we have further explored, and
directly compared, the effects of both types of stimula-
tions (anodal and cathodal tDCS) of the motor cortex.
As far as the parameters of tDCS stimulation and treat-
ment duration, we used a typical protocol for pain
treatment (21), consisting of five daily tDCS applica-
tions for 20 minutes, at 2mA of current intensity.
For sham tDCS, the stimulator was turned off after
30 sec. The sham and the real tDCS modes (anodal/
cathodal) were activated through a code by one of the
experimenters (ES), who did not participate in data
collection and patients’ clinical outcome.
Participants in the open-label trial received the
standardised acute drug withdrawal above described
for five consecutive days, then entered the follow-up,
and no application of tDCS was provided.
Participants both in the RCT and open-label trial
were not allowed to start any prophylaxis treatment
for migraine during the 12-month study period.
Efficacy end points
The primary outcome was the proportion of patients
with a reduction of at least 50% of days of migraine per
month recorded by a specific Daily Headache Diary at
12-month visit.
The secondary outcomes were the reduction of days
of migraine per month, the reduction of analgesic
intake per month, and the change in disability and
quality of life (Migraine Disability Assessment,
MIDAS; Headache Impact Test, HIT-6), catastrophis-
ing (Pain Catastrophizing Scale), depression (Beck
Depression Inventory) and state and trait anxiety
(Spielberger questionnaires), dependence attitude
(Leeds questionnaire) and allodynia intensity
(Allodynia Symptoms Checklist, ASC).
Follow-up visits
Participants enrolled both in the RCT and the open-
label trial underwent follow-up visits at 3, 6, 9, and 12
months after the end of drug withdrawal and tDCS
treatments. All clinical data included in primary and
secondary outcomes were recorded at each follow-up
visit.
Statistical analysis
Primary analysis of efficacy was performed by
intention-to-treat. The efficacy of tDCS was assessed
by binomial regression. Repeated measures analysis
of variance (ANOVA) was used in order to assess
effect of treatment and difference between treatment
groups in terms of decrease in number of days of
migraine per month and number of analgesics taken
per month throughout the 12-month study period.
Differences between groups in the secondary outcome
changes from baseline to 12-month visit were analysed
through the ANOVA adjusted for baseline values.
Statistical analysis was carried out using STATA sta-
tistical software, version 15 (StataCorp. 2017. Stata
Statistical Software: Release 15. College Station, TX:
StataCorp LLC).
Data availability
The data that support the findings of this study are
available from the corresponding author.
Results
Between December 2015 and June 2017, we consecu-
tively screened 237 patients. One hundred and two
patients were not included because they did not give
consent (31 patients), had known psychiatric comor-
bidities (25 patients), idiopathic intracranial hyperten-
sion (42 patients), or other comorbidities (four
patients). Eventually, 135 patients were randomly allo-
cated to the anodal tDCS arm (44 patients), the cath-
odal tDCS arm (45 patients), and sham arm (46
patients) (Figure 1).
Thereafter, between August 2017 and May 2018, we
consecutively screened 51 patients and eventually
enrolled 22 patients for the open-label study. Twenty-
nine patients were not included for known psychiatric
comorbidities (10 patients) or because they did not give
consent (19 patients).
At baseline, demographic variables and age of
migraine onset, days of migraine per month, and
mean analgesic drug intake per month did not differ
among groups (Table 1). At 12-month follow-up, the
proportion of patients with a reduction of at least 50%
of days of migraine per month was not significantly
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different between groups: 64.1% in anodal, 60.0% in
cathodal, 46.3% in sham and 55.0% in the open-label
arm. At 6 and 12-month follow-up, all groups showed
similar reductions of days of migraine per month
between tDCS (either cathodal, anodal or the results
obtained from the two arms of treatment, anodal plus
cathodal) and sham arms, and open label arm (Table
2). Similarly, the number of analgesics taken per month
reduced at 6 and 12-month follow-up, with no signifi-
cant differences between tDCS (either cathodal,
anodal, or the results obtained from the two arms of
treatment, anodal plus cathodal) and sham arms, and
the open-label arm (Table 3). Repeated measures anal-
ysis of variance demonstrated a significant effect of any
treatment with no difference between groups, both in
terms of number of days of migraine per month (Figure
2(a)) and number of analgesics taken per month
(Figure 2(b)). All the other outcomes improved at 12
months compared to baseline (Table 4).
Patients in both treatment groups reported no side
effects from tDCS application during the course of
therapy and during the follow-up.
Discussion
Our results confirm that tDCS did not influence the
frequency of chronic migraine in a population of
patients with medication overuse. These findings con-
firm the lack of efficacy of tDCS, as previously dem-
onstrated in a cohort of patients with chronic low back
Table 1. Demographic variables of patients enrolled in the randomised trial (anodal, cathodal, sham) and the open label trial (drug
withdrawal). Number of days of migraine and number of analgesics refer to the month prior to the enrolment.
No. of
patients (F/M)
Age,
mean SD
Age at onset,
mean SD
No. of days of
migraine/month,
mean SD
No. of
analgesics/month,
mean SD
Anodal 45 (41/4) 47.8 10.8 19.5 10.1 19.5 10.1 20.9 6.2
Cathodal 44 (36/8) 47.7 13.1 21.0 11.0 20.9 11.0 23.1 6.9
Sham 46 (37/9) 45.5 11.3 17.9 8.9 17.9 8.8 21.5 6.9
Drug withdrawal 22 (21/1) 43.5 9.2 19.3 7.3 21.8 7.8 18.7 6.7
SD: standard deviation.
Table 2. Number of days of migraine per month recorded by the Daily Headache Diary at baseline and at 6 and 12-month visit in the
patients enrolled in the randomised trial (anodal, cathodal, sham) and the open label trial (drug withdrawal).
No. of days of
migraine/month
Baseline,
mean SD
No. of days of
migraine/month
6-month follow-up,
mean SD
No. of days of
migraine/month
12-month follow-up,
mean SD
Anodal 20.4 6.6 13.3 10.2 11.0 7.5
Cathodal 23.5 7.0 11.8 8.6 11.5 8.6
Sham 21.8 6.4 12.6 8.9 13.0 7.8
Drug withdrawal 19.6 7.4 10.9 8.2 9.9 7.4
SD: standard deviation.
Table 3. Number of analgesics taken per month at baseline and at 6 and 12-month visit in the patients enrolled in the randomised
trial (anodal, cathodal, sham) and the open label trial (drug withdrawal).
No. of analgesics/month
Baseline,
mean SD
No. of analgesics/month
6-month follow-up,
mean SD
No. of analgesics/month
12-month follow-up,
mean SD
Anodal 20.9 6.2 11.4 10.2 10.6 8.4
Cathodal 23.1 6.9 10.9 9.6 10.4 10.4
Sham 21.5 6.9 12.7 11.6 12.6 8.9
Drug withdrawal 17.5 6.5 10.3 7.6 8.2 5.1
SD: standard deviation.
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pain (22). Whether tDCS might exert any positive
effect in other acute pain disorders remains
unaddressed.
Migraine can remain episodic or become a chronic
disorder, this latter having a high burden for patients’
quality of life and health system costs, mainly when
complicated by MO. Unknown individual genetic
backgrounds, behavioural profiles, and psychiatric
comorbidities likely play key roles in driving its
course. For these reasons migraine, in particular chron-
ic migraine, remains a complex disease that is difficult
to treat. In real life, most CM patients record a month-
ly use of 15–25 analgesics, less than 5–8 days free of
migraine per month, several failed pharmacological
prophylaxis, and a high rate of relapse after drug with-
drawal. The design of clinical studies aiming to unravel
the effect of treatments in CM should acknowledge the
overall context, consider clinically meaningful changes,
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Figure 2. Repeated measures analysis of variance showing a significant effect of any treatment compared to baseline as to (a) number
of days of migraine per month (p< 0.01) and (b) number of analgesics taken per month (p< 0.01), with no difference between groups
(p¼ 0.39 and 0.12, respectively).
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and measure the changes in a clinically meaningful time
frame. Undoubtedly, long-term efficacy of treatments
should be always the primary outcome in trials. What
follows is that short and unpowered studies, including
patients whose features may be not representative of
those commonly seen in clinical practice, carry the
intrinsic risk of drawing biased conclusions. This
might have been the case for the efficacy of botulin
toxin, which when tested in a solid clinical trial, was
not confirmed to provide any additional benefit over
acute drug withdrawal (3), as a Cochrane review had
anticipated (23).
We chose as the primary outcome of the RCT the
proportion of patients with a reduction of at least 50%
in days with migraine at 12-month follow-up, to pro-
vide evidence of a concrete and long-lasting effect, and
as secondary outcomes the reduction of analgesic
intake per month at 6 and 12 months to provide
hints of the effect of treatment on MO.
Since acute drug withdrawal should be considered
the first step for managing CM with MO patients
(2,24), we aimed at assessing whether tDCS, which
was claimed to have positive effects on the course of
the disease (5,6,25–29), had an additional short-, mid-
and long-term effect. To achieve our aim, we compared
anodal and cathodal tDCS directly against sham stim-
ulation, and indirectly against acute drug withdrawal
alone in patients who did not undergo any pharmaco-
logical prophylaxis treatment for the entire study
period of 1 year. This latter comparison provided an
analysis of efficacy against the standard of care, namely
acute drug withdrawal, even though within the longer
setting of an RCT that, by definition, differed from the
clinical practice. For example, patients enrolled could
trust in visits scheduled with intervals shorter than in
the common clinical practice and in the availability of
access to consultation. This could have partially biased
the translational interpretation of RCT results, while
offering hints of the opportunity to implement clinical
practice with such a personalised pain management
approach, even if this required some additional organ-
isational effort.
Pharmacological options for prophylaxis are differ-
ent, and the drug is generally selected based on
patients’ clinical history, physical, and psychological
comorbidities. On the other hand, pharmacological
treatments are sometimes barely tolerated because of
their side effects, so the adherence to therapy is often
low (30). In the last decades, non-pharmacological
methods have been proposed for treating patients
with CM, including neuromodulation techniques.
Based on the concept that CM might be associated to
central sensitisation, the ability of tDCS to modulate
pain-related neural networks has been considered the
explanation for the positive findings in small and pre-
liminary studies, for which confirmatory trials have
been strongly suggested (14–17,31).
Our study provided robust evidence that tDCS did
not change the proportion of patients with 50% reduc-
tion of days of migraine compared to sham stimulation
and drug withdrawal alone. Moreover, we found that
the monthly reduction both in the number of days of
migraine and number of analgesics was significant in all
the treatment arms, with no difference between groups.
Similarly, all secondary outcome measures that encom-
passed quality of life, mood and other behavioural and
symptom questionnaires improved compared to base-
line, with no difference between groups except for cat-
astrophising, which improved better in the tDCS
groups compared to the sham group, even though
with a score difference that was unlikely to be clinically
meaningful. Overall, these results were achieved after
acute drug withdrawal by a standardised program of
pain management, including behavioural and
Table 4. Outcome changes from baseline to 12-month visit recorded in the randomised controlled trial. p-values are from the
analysis of variance (ANOVA) between groups adjusted for baseline value. Migraine Disability Assessment (MIDAS); Headache Impact
Test (HIT-6); state and trait anxiety (Spielberger questionnaires (STAIS and STAIT)); depression (Beck Depression Inventory (BDI));
dependence attitude (Leeds questionnaire (LDQ)); catastrophising attitude (Pain Catastrophizing Scale (PCS)); allodynia intensity
(Allodynia Symptoms Checklist (ASC)).
Outcome
Anodal tDCS,
mean SD
Cathodal tDCS,
mean SD
Sham,
mean SD p
MIDAS 45.4 48.4 27.8 67.5 17.1 46.1 0.60
HIT-6 4.4 9.1 4.7 8.8 3.6 6.9 0.28
STAIS 2.3 13.1 1.5 12.2 4.4 9.0 0.99
STAIT 6.8 9.8 3.0 9.2 4.2 12.0 0.27
BDI 6.6 7.4 4.7 8.1 5.0 7.5 0.51
LDQ 5.3 6.8 6.1 7.5 4.8 5.9 0.63
PCS 10.3 13.3 10.1 13.7 8.9 10.1 0.02
ASC 1.4 3.9 0.9 5.0 1.3 4.6 0.94
SD: standard deviation.
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educational measures, short-term scheduled visits, and
availability of access to consultation.
Such results at 6 and 12 months appear to be of
particular interest considering that the patients, who
had failed at least two previous prophylaxis therapies,
were not allowed to take any pharmacological prophy-
laxis for migraine for the entire study period. They
have been educated to use abortive medications just
in the case of very intense pain attacks, following the
standard of care of our Headache Centre. All patients
were also educated to apply some behavioural meas-
ures to avoid pain or to manage it, such as practising
physical activity, having regular meals and regular
sleep habits during the period of the study program
and follow-up (32). Even though these optional
approaches were not standardised and controlled, the
compliance of patients to the entire study program,
including these behavioural suggestions, could have
contributed to the positive outcome.
The improvement of the psychological variables
known to influence the course of CM was in keeping
with the overall improvement of the somatic symp-
toms. In particular, all secondary measures of impact
of migraine in daily life and activities, anxiety, depres-
sion, and catastrophising improved compared to
baseline.
The program to which patients could adhere both in
the RCT and open-label study was different from the
regular clinical practice. Patients were seen regularly
every 3 months, and they were free to contact the neu-
rologists any time they needed to be reinforced.
Supplemental clinical contacts by phone call or
emails were needed in 10% of cases, whereas three
patients needed one supplemental visit. This particular
setting of treatment could be important to reinforce the
clinical benefit, by increasing patients’ confidence in
their abilities to manage pain, while ensuring they
would be supported by clinicians when needed. A sig-
nificant percentage of patients with CM have an over-
use of analgesics (33), and it was reported that acute
drug withdrawal could also induce the reduction of
migraine frequency in the long term (34,35).
In conclusion, our study provided conclusive evi-
dence that tDCS did not influence the course of CM
with MO after acute drug withdrawal in the short and
long term. It confirmed that acute drug withdrawal is a
well-tolerated and effective first-line treatment. Finally,
it strengthened the concept that programs including
behavioural and educational measures for pain man-
agement, short-term scheduled visits and availability
of access to consultation could favour long-term
improvement and low rate of relapses.
Our study might have some limitations. The open-
label group was not added as one further arm of the
double-blind part of the trial. However, results might
have been biased by the lack of any active or sham
tDCS procedure, and therefore would not have been
comparable. Even though the open label group had the
intrinsic limitation of a non-parallel analysis, we
thought it could have provided a clinically meaningful
comparison between the results from the RCT and the
current clinical practice, while ensuring the integrity of
the RCT. Moreover, patients enrolled could trust in
visits scheduled with intervals shorter than in
common clinical practice and in the availability of
access to consultation. This could have partially
biased the translational interpretation of RCT results,
while offering hints on the opportunity to implement
clinical practice with such a personalised pain manage-
ment approach, even if it requires some additional
organisational effort.
Clinical implications
• CM patients are difficult to treat, and the regular use of medications can lead to an increased frequency and
intensity of migraine attacks. Such association with medication overuse (MO) makes the overall treatment
even more challenging.
• The efficacy of neurostimulation techniques, in particular tDCS, in treating migraine has been tested using
different approaches in several clinical studies with inconclusive results.
• We designed a placebo-controlled, double-blind, randomised clinical trial (RCT) combined with an ensu-
ing open label study to assess, over 1-year follow-up, short-, mid- and long-term efficacy of tDCS in
patients with CM and MO after acute drug withdrawal and no migraine prophylaxis.
• Our study provided conclusive evidence that tDCS did not influence the course of CM with MO after acute
drug withdrawal in the short and long term, and confirmed that acute drug withdrawal is a well-tolerated
and effective first line treatment.
• The study strengthened the concept that tailored programs of pain management, including behavioural and
educational measures, short-term scheduled visits and availability of access to consultation could favour
long-term improvement and low rate of relapses.
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